Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Paratek reveals Nuzyra data on pneumonia and skin infections

By Brian Buntz | September 23, 2021

ParatekAntibiotic specialist Paratek Pharmaceuticals (NSDQ:PRTK) recently shared new data related to its tetracycline-class antibacterial Nuzyra (omadacycline).

Specifically, the company provided real-world data related to pneumonia, skin infections and nontuberculous mycobacterial infections in presentations at IDWeek 2021, a virtual conference organized by several infectious disease associations. The company also has collected data on in vitro activity related to B. anthracis, the bacterium that causes anthrax.

“With these presentations, Paratek continues to deepen the understanding of the utility of Nuzyra for serious community-acquired infections and nontuberculous mycobacterial infections, a rare disease for which there are no approved therapies,” said Randy Brenner, chief development & regulatory officer of Paratek, in a statement. “Notably, we will share the results of two studies examining the potential of Nuzyra in treating anthrax infections, one of the agents most likely to be used in a bioterrorism attack, and a health economics study examining healthcare resource utilization among patients treated with Nuzyra for skin infections and pneumonia.”

Last month, the company announced that the FDA granted the company orphan drug designation for Nuzyra to nontuberculous mycobacteria infections.

 


Filed Under: Infectious Disease
Tagged With: FDA, Nuzyra, omadacycline, Paratek, Paratek Pharmaceuticals
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE